Back to search resultsSummaryRMgm-4359
|
Successful modification | The parasite was generated by the genetic modification |
The mutant contains the following genetic modification(s) | Gene disruption |
Reference (PubMed-PMID number) |
Reference 1 (PMID number) : 28902970 |
MR4 number | |
top of page | |
Parent parasite used to introduce the genetic modification | |
Rodent Malaria Parasite | P. berghei |
Parent strain/line | P. berghei ANKA |
Name parent line/clone | Not applicable |
Other information parent line | |
top of page | |
The mutant parasite was generated by | |
Name PI/Researcher | Sayers CP, McFadden GI, Goodman CD |
Name Group/Department | School of BioSciences |
Name Institute | University of Melbourne |
City | Parkville, Victoria |
Country | Australia |
top of page | |
Name of the mutant parasite | |
RMgm number | RMgm-4359 |
Principal name | KO-PbANKA_0903500 |
Alternative name | |
Standardized name | |
Is the mutant parasite cloned after genetic modification | No |
top of page | |
Phenotype | |
Asexual blood stage | Not essential for blood stage growth/multiplication |
Gametocyte/Gamete | Not tested |
Fertilization and ookinete | Not tested |
Oocyst | Not tested |
Sporozoite | Not tested |
Liver stage | Not tested |
Additional remarks phenotype | Mutant/mutation Candidates were selected from P. falciparum putative membrane transporters belonging to known transport families and selected members of the predicted P. falciparum apicoplast proteome with multiple TMDs. Many P. falciparum membrane transporters have seven or more TMDs, whilst some have six or fewer. Without biological data to confirm membrane transport activity, candidate proteins predicted to have at least six TMDs were selected. Although multiple TMDs is a minimum requirement of most membrane transporters, some of these proteins may be integral membrane proteins with other functions. See also mutant RMgm-1167 lacking expression of PbANKA_0903500, showing a strongly reduced growth rate of blood stages. |
top of page | |||||||||||||||||||||||||
Details of the target gene | |||||||||||||||||||||||||
Gene Model of Rodent Parasite | PbANKA_0903500 | ||||||||||||||||||||||||
Gene Model P. falciparum ortholog | PF3D7_1145500 | ||||||||||||||||||||||||
Gene product | ABC transporter B family member 3, putative | ||||||||||||||||||||||||
Gene product: Alternative name | ABCB3; MDR3 | ||||||||||||||||||||||||
top of page | |||||||||||||||||||||||||
Details of the genetic modification | |||||||||||||||||||||||||
Inducable system used | No | ||||||||||||||||||||||||
Additional remarks inducable system | |||||||||||||||||||||||||
Type of plasmid/construct used | (Linear) plasmid double cross-over | ||||||||||||||||||||||||
PlasmoGEM (Sanger) construct/vector used | Yes | ||||||||||||||||||||||||
Name of PlasmoGEM construct/vector | - | ||||||||||||||||||||||||
Modified PlasmoGEM construct/vector used | No | ||||||||||||||||||||||||
Plasmid/construct map | |||||||||||||||||||||||||
Plasmid/construct sequence | |||||||||||||||||||||||||
Restriction sites to linearize plasmid | |||||||||||||||||||||||||
Partial or complete disruption of the gene | Complete | ||||||||||||||||||||||||
Additional remarks partial/complete disruption | |||||||||||||||||||||||||
Selectable marker used to select the mutant parasite | hdhfr/yfcu | ||||||||||||||||||||||||
Promoter of the selectable marker | eef1a | ||||||||||||||||||||||||
Selection (positive) procedure | pyrimethamine | ||||||||||||||||||||||||
Selection (negative) procedure | No | ||||||||||||||||||||||||
Additional remarks genetic modification | |||||||||||||||||||||||||
Additional remarks selection procedure | |||||||||||||||||||||||||
Primer information: Primers used for amplification of the target sequences
Primer information: Primers used for amplification of the target sequences
| |||||||||||||||||||||||||
top of page |